- Home
- ZNTL vs SAVA Comparison
ZNTL vs SAVA Comparison
Compare ZNTL & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- SAVA
- Stock Information
- Founded
- ZNTL 2014
- SAVA 1998
- Country
- ZNTL United States
- SAVA United States
- Employees
- ZNTL N/A
- SAVA N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- SAVA Health Care
- Exchange
- ZNTL Nasdaq
- SAVA Nasdaq
- Market Cap
- ZNTL 105.8M
- SAVA 102.4M
- IPO Year
- ZNTL 2020
- SAVA N/A
- Fundamental
- Price
- ZNTL $1.49
- SAVA $2.11
- Analyst Decision
- ZNTL Buy
- SAVA Hold
- Analyst Count
- ZNTL 7
- SAVA 1
- Target Price
- ZNTL $8.46
- SAVA $2.00
- AVG Volume (30 Days)
- ZNTL 805.4K
- SAVA 517.9K
- Earning Date
- ZNTL 11-11-2025
- SAVA 11-06-2025
- Dividend Yield
- ZNTL N/A
- SAVA N/A
- EPS Growth
- ZNTL N/A
- SAVA N/A
- EPS
- ZNTL N/A
- SAVA N/A
- Revenue
- ZNTL $26,865,000.00
- SAVA N/A
- Revenue This Year
- ZNTL N/A
- SAVA N/A
- Revenue Next Year
- ZNTL N/A
- SAVA N/A
- P/E Ratio
- ZNTL N/A
- SAVA N/A
- Revenue Growth
- ZNTL N/A
- SAVA N/A
- 52 Week Low
- ZNTL $1.01
- SAVA $1.15
- 52 Week High
- ZNTL $5.44
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- ZNTL 43.18
- SAVA 44.15
- Support Level
- ZNTL $1.60
- SAVA $2.12
- Resistance Level
- ZNTL $2.02
- SAVA $2.19
- Average True Range (ATR)
- ZNTL 0.13
- SAVA 0.10
- MACD
- ZNTL -0.04
- SAVA -0.02
- Stochastic Oscillator
- ZNTL 5.36
- SAVA 6.45
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.